Short- and long-term effects of pulmonary rehabilitation for idiopathic pulmonary fibrosis: a systematic review and meta-analysis

Cheng, Li; Tan, Botao; Yin, Ying; Wang, Sanrong; Jia, Lang; Warner, Gerry; Jia, Gongwei; Jiang, Wei

doi:10.1177/0269215518779122

Cited by 30 publications

(49 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, no clear conclusions can be drawn in severe ILD and data on long-term effects of pulmonary rehabilitation in this advanced cohort are still sparse [156]. Current evidence on pulmonary rehabilitation in IPF shows significant short-term effects on improving exercise capacity (6MWD) and HRQL, while long-term effects are not maintained [157]. In addition, pulmonary rehabilitation has been shown to be useful in patients referred to lung transplantation [158].…”

Section: Pulmonary Rehabilitationmentioning

confidence: 99%

The therapy of idiopathic pulmonary fibrosis: what is next?

et al. 2019

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial lung disease, characterised by progressive scarring of the lung and associated with a high burden of disease and early death. The pathophysiological understanding, clinical diagnostics and therapy of IPF have significantly evolved in recent years. While the recent introduction of the two antifibrotic drugs pirfenidone and nintedanib led to a significant reduction in lung function decline, there is still no cure for IPF; thus, new therapeutic approaches are needed. Currently, several clinical phase I–III trials are focusing on novel therapeutic targets. Furthermore, new approaches in nonpharmacological treatments in palliative care, pulmonary rehabilitation, lung transplantation, management of comorbidities and acute exacerbations aim to improve symptom control and quality of life. Here we summarise new therapeutic attempts and potential future approaches to treat this devastating disease.

show abstract

Section: Pulmonary Rehabilitationmentioning

confidence: 99%

The therapy of idiopathic pulmonary fibrosis: what is next?

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Depression and anxiety have been described in around 25% of patients with IPF [55][56][57] . Depression and chronic physical illness are in reciprocal relationship with one another: not only do many chronic diseases cause higher rates of depression, but depression has been shown to decrease the potential benefits of the treatment approach 58 . Depression and anxiety may also impact on medication adherence 55,56 (Fig.…”

Section: Mental Wellbeing and Physical Healthmentioning

confidence: 99%

Comprehensive Care in Pulmonary Fibrosis

Molina-Molina¹,

Wijsenbeek²

2021

BRN

View full text Add to dashboard Cite

Pulmonary fibrosis is a respiratory condition that associates progressive loss of quality of life mainly due to respiratory failure with emotional impairment due to the loss of autonomy and the poor prognosis. These clinical conditions and the poor prognosis would require a strategy closer to lung cancer than to other respiratory diseases. However, most centres that manage patients with pulmonary fibrosis have not enough resources to properly provide the multidisciplinary approach that they require. Idiopathic pulmonary fibrosis (IPF) is the most frequent and lethal form of lung fibrosis, for which two anti-fibrotic drugs have demonstrated to slowdown disease progression. Both drugs require a close monitoring to ensure adherence and to prevent or reduce adverse effects. Currently, there is an increased demand of improving the multidisciplinary integral treatment of IPF and other lung fibrotic entities to optimise drug benefits and quality of life during the different stages of the disease, including end of life.

show abstract

“…Another issue is one associated with individualisation and standardisation of the rehabilitation programme, taking into account the patient's capabilities and preferences and resulting, among others, from the degree of functional impairment, need for oxygen therapy and comorbidities. Another controversial question is that of the duration of the effects of rehabilitation, since many authors claim that the effects last up to 6 [307,313,321], 11 [326] or even 12 months [325] after completing the programme, while others do not confirm its lasting beneficial effects in a longer term [315,321]. Lack of unequivocal data confirming distant effect indicates it is necessary to use rehabilitation in a continuous and systematic way.…”

Section: Commentarymentioning

confidence: 99%

“…The most recent meta-analyses of 5 randomised trials involving more than 130 IPF patients divided into a group of subjects receiving rehabilitation and a control group demonstrated an improvement in exercise tolerance, reduction of symptoms and quality of life improvement [320]. Another meta-analysis of 4 randomised trials (a total of 142 subjects) confirmed beneficial short-term effects of rehabilitation on exercise capacity and quality of life but failed to confirm any distant effects [321]. The most recent meta-analysis of 7 studies involving 190 IPF patients demonstrated improved exercise capacity measured as distance in the 6MWT and improved quality of life [322].…”

Section: Introductionmentioning

confidence: 99%